scholarly journals Low Birth Weight Is Linked to Age-Related Macular Degeneration: Results From the Population-Based Gutenberg Health Study (GHS)

2019 ◽  
Vol 60 (14) ◽  
pp. 4943 ◽  
Author(s):  
Achim Fieß ◽  
Hisham Elbaz ◽  
Christina A. Korb ◽  
Stefan Nickels ◽  
Andreas Schulz ◽  
...  
Keyword(s):  
Birth Weight ◽  
Low Birth Weight ◽  
Macular Degeneration ◽  
Population Based ◽  
Age Related Macular Degeneration ◽  
Health Study ◽  
Gutenberg Health Study ◽  
Age Related

scholarly journals Five-year cumulative incidence and progression of age-related macular degeneration: results from the German population-based Gutenberg Health Study (GHS)

2021 ◽  
Author(s):  
Christina A. Korb ◽  
Hisham Elbaz ◽  
Alexander K. Schuster ◽  
Stefan Nickels ◽  
Katharina A. Ponto ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Cumulative Incidence ◽  
Population Based ◽  
Age Related Macular Degeneration ◽  
Fundus Photography ◽  
Health Study ◽  
German Population ◽  
Gutenberg Health Study ◽  
Age Related

Abstract Purpose Age-related macular degeneration (AMD) is a major cause of visual impairment and blindness. This study evaluates the incidence and progression of AMD in a large German cohort. Methods The Gutenberg Health Study (GHS) is a population-based, prospective, observational cohort study in Germany that includes 15,010 participants between 35 and 74 years of age. The baseline examination, including fundus photography, was conducted between 2007 and 2012, and the 5-year follow-up examination was performed between 2012 and 2017. AMD grading of fundus photographs was performed according to the Rotterdam Eye Study classification. The 5-year cumulative incidence and progression of AMD were calculated. Poisson regression analysis was conducted to investigate factors associated with the cumulative incidence and progression of AMD. Results Six-thousand-eight-hundred-eighty-eight participants (49.8%, n = 3427 female) were included in the analysis. AMD prevalence was 8.5% [95% CI: 7.9–9.2%] at baseline and 10.3% [95% CI: 9.6–11.1%] at follow-up. The cumulative 5-year-incidence was 2.0% [1.7–2.4%]. AMD progression within 5 years was seen in 18.1% [95% CI: 15.1–21.5%] of the participants. AMD incidence and AMD progression were associated with higher age, for each 10-year increase in age, the risk of AMD doubles (RR = 2.30), and the risk of progression of the disease is increased by 1.6. while AMD incidence also with pseudophakic status. Conclusions In summary, this population-based sample provides substantial epidemiologic data from a large German cohort, including data on progression and cumulative incidence of macular degeneration in younger age groups. AMD progression over 5 years is common in the German population, 18.1% of subjects with AMD showed progression in at least one eye in this time frame and is associated with higher age. Nevertheless, although usually defined to occur over the age of 50, in this cohort AMD occurred in 0.5% and AMD progression occurred in 5.4% of those already affected in the youngest age group before 50 years of age.

scholarly journals Plasma Lutein, a Nutritional Biomarker for Development of Advanced Age-Related Macular Degeneration: The Alienor Study

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 2047
Author(s):  
Bénédicte M. J. Merle ◽  
Audrey Cougnard-Grégoire ◽  
Jean-François Korobelnik ◽  
Wolfgang Schalch ◽  
Stéphane Etheve ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
High Performance ◽  
Population Based ◽  
Age Related Macular Degeneration ◽  
Cox Proportional Hazard ◽  
Age Related ◽  
Cox Proportional Hazard Models ◽  
Adjusted Model ◽  
Reduced Risk

Lutein and zeaxanthin may lower the risk of age-related macular degeneration (AMD). We evaluated the associations of plasma lutein and zeaxanthin with the incidence of advanced AMD in the Alienor study (Antioxydants Lipides Essentiels Nutrition et Maladies Oculaires). Alienor study is a prospective population-based cohort of 963 residents of Bordeaux, France, who were 73 years or older at baseline (2006–2008). The present study included 609 participants with complete ophthalmologic and plasma carotenoids data. Examinations were performed every two years over an eight-year period (2006 to 2017). Plasma lutein and zeaxanthin were determined at baseline from fasting blood samples using high-performance liquid chromatography. Cox proportional hazard models were used to assess associations between plasma lutein, zeaxanthin, and their (total cholesterol (TC) + triglycerides (TG)) ratios with AMD. Among the 609 included participants, 54 developed advanced incident AMD during a median follow-up time of 7.6 years (range 0.7 to 10.4). Participants with higher plasma lutein had a reduced risk for incident advanced AMD in the fully adjusted model (HR = 0.63 per 1-SD increase (95% CI, 0.41–0.97), p = 0.03). A similar association was observed using the lutein/(TC + TG) ratio (HR = 0.59 (95% CI, 0.39–0.90), p = 0.01). No associations were evidenced for other carotenoids. Higher plasma lutein was associated with a 37% reduced risk of incident advanced AMD.

A Population-based Study on the Prevalence and Associated Factors of Age-related Macular Degeneration in Northern Iran the Gilan Eye Study

2020 ◽  
Vol 27 (3) ◽  
pp. 209-218
Author(s):  
Hassan Behboudi ◽  
Homayoun Nikkhah ◽  
Yousef Alizadeh ◽  
Marzieh Katibeh ◽  
Mojgan Pakbin ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Associated Factors ◽  
Population Based ◽  
Age Related Macular Degeneration ◽  
Northern Iran ◽  
Population Based Study ◽  
Age Related

scholarly journals Thyroid function and age-related macular degeneration: a prospective population-based cohort study - the Rotterdam Study

BMC Medicine ◽  
2015 ◽  
Vol 13 (1) ◽  
Author(s):  
Layal Chaker ◽  
Gabriëlle HS Buitendijk ◽  
Abbas Dehghan ◽  
Marco Medici ◽  
Albert Hofman ◽  
...  
Keyword(s):  
Cohort Study ◽  
Macular Degeneration ◽  
Thyroid Function ◽  
Population Based ◽  
Age Related Macular Degeneration ◽  
Rotterdam Study ◽  
Age Related

scholarly journals Contribution of the Nurses’ Health Study to the Epidemiology of Cataract, Age-Related Macular Degeneration, and Glaucoma

2016 ◽  
Vol 106 (9) ◽  
pp. 1684-1689 ◽  
Author(s):  
Jae H. Kang ◽  
Juan Wu ◽  
Eunyoung Cho ◽  
Soshiro Ogata ◽  
Paul Jacques ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Health Study ◽  
Age Related

scholarly journals Association Between Age‐Related Macular Degeneration and Risk of Heart Failure: A Population‐Based Nested Case‐Control Study

2021 ◽  
Author(s):  
Chao‐Chien Chang ◽  
Chi‐Hung Huang ◽  
Yu‐Ching Chou ◽  
Jin‐Yin Chang ◽  
Chien‐An Sun
Keyword(s):  
Heart Failure ◽  
Macular Degeneration ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Increased Risk ◽  
Nested Case Control ◽  
Control Study

Background Heart failure (HF) is a major health problem worldwide because of its high morbidity and mortality. Recently, the role of the microvasculature in HF has gained more attention. Age‐related macular degeneration (AMD) is manifested through geographic atrophy or the development of neovascularization. However, there are limited data on investigations about the association between AMD and HF. The purpose of this study was to examine the association of AMD with the risk of HF in a large population‐based cohort of men and women. Methods and Results A nested case‐control study using Taiwan’s National Health Insurance Research Database was conducted between 2000 and 2012. Newly diagnosed heart failure cases (n=13 721) and matched controls (n=54 884) in the database were recruited. Patients who had ≥2 clinical visits with a diagnosis of AMD at least 1 year before the diagnosis of HF were identified as patients with AMD. Conditional logistic regressions were performed to calculate odds ratios and 95% CIs to assess the association between AMD and risk of HF. AMD was associated with a 1.58‐fold increased risk of HF (95% CI, 1.16–1.87) ( P <0.001) after adjustment for potential confounders. This significant association was evident in both nonexudative and exudative AMD subgroups. Conclusions Our study provides evidence that AMD was associated with an increased risk of HF. Further molecular and pathophysiological studies are needed to clarify the underlying pathophysiological mechanisms behind the association of AMD with HF.

scholarly journals Association Between Silymarin Use and Age-related Macular Degeneration in Patients With Chronic Hepatic Diseases: a Population-based Retrospective Cohort Study

2021 ◽  
Author(s):  
Mu-Ming Chien ◽  
Hsiu-Chen Lin ◽  
Li-Fen Lee ◽  
Joseph Jordan Keller ◽  
Li-Hsuan Wang
Keyword(s):  
Cohort Study ◽  
Macular Degeneration ◽  
Retrospective Cohort Study ◽  
Retrospective Cohort ◽  
Population Based ◽  
Hazard Ratio ◽  
Age Related Macular Degeneration ◽  
Defined Daily Dose ◽  
Hepatic Diseases ◽  
Age Related

Abstract Silymarin is a bioflavonoid compound mostly used in patients with chronic hepatic diseases (CHDs). It has been shown to inhibit retinal angiogenesis in in vitro and in vivo animal studies. Age-related macular degeneration (AMD) is a leading cause of vision impairment worldwide, and no definite preventive measures for AMD exist at present. Through this study, we aimed to investigate whether the use of silymarin affects the risk of AMD in patients with CHDs. Cox proportional hazard models were used to assess the hazard ratio (HR) of AMD in this population-based retrospective cohort study. The CHDs was associated with a higher risk of AMD (adjusted hazard ratio (aHR): 1.33, 95% CI 1.22–1.46), and the use of silymarin reduced the risk of AMD among patients with CHDs (aHR: 0.76, 95% CI: 0.67–0.87). A higher accumulative dose (defined daily dose [DDD] < 631 mg) of silymarin was associated with a lower risk of AMD, but the difference was nonsignificant. In conclusion, CHDs were associated with a higher incidence of AMD, and the use of silymarin was associated with a reduced risk of AMD in patients with CHDs. However, a higher accumulative DDD of silymarin did not reduce the risk of AMD.

Sign in / Sign up

Export Citation Format

Share Document